Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by I-xazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

Ludwig, H; Poenisch, W; Knop, S; Egle, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Krenosz, KJ; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Melchardt, T; Greil, R; Zojer, N.

Br J Cancer. 2019 Oct;121(9):751-757. doi: 10.1038/s41416-019-0581-8. Epub 2019 Sep 27.

https://pubmed.ncbi.nlm.nih.gov/31558804/